Fmoc-Cha-OH | Carboxylic Acids

Fmoc-Cha-OH is a protected cyclohexylalanine derivative with the amino group protected by 9-fluorenylmethoxycarbonyl (Fmoc), suitable for peptide synthesis.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of Fmoc-Cha-OH Purity: 97% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of Fmoc-Cha-OH

CAS No. :	135673-97-1
Formula :	C₂₄H₂₇NO₄
M.W :	393.48
SMILES Code :	O=C(O)[C@@H](NC(OCC1C2=C(C3=C1C=CC=C3)C=CC=C2)=O)CC4CCCCC4
MDL No. :	MFCD00065614
InChI Key :	HIJAUEZBPWTKIV-QFIPXVFZSA-N
Pubchem ID :	978326

Safety of Fmoc-Cha-OH

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Application In Synthesis of Fmoc-Cha-OH

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 135673-97-1 ]

[ 135673-97-1 ] Synthesis Path-Downstream 1~31

1
[ 4100-13-4 ]
[ 35661-40-6 ]
[ 119831-72-0 ]
[ 135673-97-1 ]
[1,2,3]Thiadiazole-4-carboxylic acid {(S)-1-[(S)-1-((S)-1-carbamoyl-2-phenyl-ethylcarbamoyl)-4-guanidino-butylcarbamoyl]-2-cyclohexyl-ethyl}-amide [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,1999,vol. 9,p. 1423 - 1428.

2
[ 122889-11-6 ]
[ 35737-15-6 ]
[ 35661-38-2 ]
[ 135673-97-1 ]
Cbz-His-OH [ No CAS ]
[(R)-1-((R)-1-{(R)-2-Benzyloxy-1-[(R)-1-((S)-1-carbamoyl-ethylcarbamoyl)-2-(1H-indol-3-yl)-ethylcarbamoyl]-ethylcarbamoyl}-2-cyclohexyl-ethylcarbamoyl)-2-(1H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester [ No CAS ]

References: [1]Journal of Medicinal Chemistry,1997,vol. 40,p. 192 - 200.

3
[ 35661-60-0 ]
[ 71989-18-9 ]
[ 104091-08-9 ]
[ 135673-97-1 ]
H-Cys(Trt)-2-chlorotrityl resinFmoc-Asp(OtBu)-OH [ No CAS ]
(S)-4-{(S)-2-[(R)-2-((S)-2-Amino-3-carboxy-propionylamino)-4-carboxy-butyrylamino]-4-methyl-pentanoylamino}-4-[(S)-1-((R)-1-carboxy-2-mercapto-ethylcarbamoyl)-2-cyclohexyl-ethylcarbamoyl]-butyric acid [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2001,vol. 11,p. 203 - 206.

4
[ 35661-60-0 ]
[ 71989-18-9 ]
[ 108-24-7 ]
[ 104091-08-9 ]
[ 135673-97-1 ]
H-Cys(Trt)-2-chlorotrityl resinFmoc-Asp(OtBu)-OH [ No CAS ]
(S)-4-{(S)-2-[(R)-2-((S)-2-Acetylamino-3-carboxy-propionylamino)-4-carboxy-butyrylamino]-4-methyl-pentanoylamino}-4-[(S)-1-((R)-1-carboxy-2-mercapto-ethylcarbamoyl)-2-cyclohexyl-ethylcarbamoyl]-butyric acid [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2001,vol. 11,p. 203 - 206.

5
[ 35661-60-0 ]
[ 71989-23-6 ]
[ 104091-08-9 ]
[ 135673-97-1 ]
[ 622841-11-6 ]

References: [1]Bioorganic and Medicinal Chemistry,2003,vol. 11,p. 2955 - 2963.

6
[ 135673-97-1 ]
[ 148983-03-3 ]

References: [1]Journal of Medicinal Chemistry,1994,vol. 37,p. 3630 - 3638.

7
[ 35661-40-6 ]
[ 71989-18-9 ]
[ 125238-99-5 ]
[ 135673-97-1 ]
N-[(9-fluorenyl)methoxycarbonyl]-4-chloro-L-phenylalanine [ No CAS ]
[ 1186310-44-0 ]

References: [1]Bioorganic and Medicinal Chemistry,2009,vol. 17,p. 5229 - 5237.

8
[ 132684-59-4 ]
[ 125238-99-5 ]
[ 135673-97-1 ]
Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine [ No CAS ]
[ 1186310-46-2 ]

References: [1]Bioorganic and Medicinal Chemistry,2009,vol. 17,p. 5229 - 5237.

9
C₉H₁₀NO₂Pol [ No CAS ]
[ 122889-11-6 ]
[ 86123-10-6 ]
[ 84624-17-9 ]
[ 135673-97-1 ]
[ 1252661-22-5 ]

References: [1]Bioorganic and Medicinal Chemistry,2010,vol. 18,p. 6822 - 6856.

10
Phe-Wang resin [ No CAS ]
[ 122889-11-6 ]
[ 77128-73-5 ]
[ 84624-17-9 ]
[ 135673-97-1 ]
[ 1190394-43-4 ]

References: [1]Bioorganic and Medicinal Chemistry,2010,vol. 18,p. 6822 - 6856.

11
[ 50881-96-4 ]
[ 125238-99-5 ]
[ 135673-97-1 ]
[ 1276031-39-0 ]

Yield	Reaction Conditions	Operation in experiment
95%		The molecular scaffold 3 was synthesized using standard solid-phase peptide synthesis methods. The 2-chlorotrityl-chloride resin (Novabiochem, loading 1.4 mmol/g) was used as solid support. For loading of the resin (100 mg, 0.14 mmol) 2 equiv. Fmoc-protected amino acid and 3 equiv. DIPEA (74 mul, 0.42 mmol) were dissolved in 2 ml CH2Cl2 and the reaction mixture was added to the resin. The reaction mixture was shaken overnight at room temperature. The resin was washed three times with 2 ml CH2Cl2 and 2 ml DMF. For Fmoc-deprotection the resin was treated two times for 15 min. with 2 ml 30 percent piperidine/DMF. A standard protocol was used for solid phase peptide synthesis: 4 equiv. Fmoc-protected amino acid, 4 equiv. HBTU (212 mg, 0.56 mmol), 4 equiv. HOBt (76 mg, 0.56 mmol) and 8 equiv. DIPEA (196 ml, 1.12 mmol) were dissolved in 2 ml CH2Cl2/DMF (1/1; v/v). The reaction mixture was stirred 20 min. at room temperature and then added to the resin. The reaction mixture was shaken for 2 hours at room temperature.For the cleavage of the peptide 3 from the solid-phase the resin was treated two times for 15 min. with 2 ml 2 percent TFA/CH2Cl2 (v/v). The solvent was co-evaporated with toluene under reduced pressure and the product was purified by preparative HPLC (H2O + 0.1 percent TFA; 10-95 percent CH3CN, 15 min, 120 ml/min, column: Sun Fire 50x100 mm, Waters).

References: [1]Bioorganic and Medicinal Chemistry,2011,vol. 19,p. 1055 - 1061.

12
[ 77128-73-5 ]
[ 135673-97-1 ]
[ 137018-93-0 ]
[ 1616762-23-2 ]